Predictive factors for response to lamivudine in chronic hepatitis B
Rev. Inst. Med. Trop. Säo Paulo
; 42(4): 189-96, July-Aug. 2000. tab, graf
Article
em En
| LILACS
| ID: lil-266051
Biblioteca responsável:
BR1.1
ABSTRACT
BACKGROUND:
Lamivudine has been shown to be an efficient drug for chronic hepatitis B (CHB) treatment.AIM:
To investigate predictive factors of response, using a quantitative method with high sensitivity.METHODS:
We carried out a prospective trial of lamivudine in 35 patients with CHB and evidence for viral replication, regardless to their HBeAg status. Lamivudine was given for 12 months at 300 mg daily and 150 mg thereafter. Response was considered when DNA was undetectable by PCR after 6 months of treatment. Viral replication was monitored by end-point dilution PCR. Mutation associated with resistance to lamivudine was detected by DNA sequencing in non-responder patients.RESULTS:
Response was observed in 23/35 patients (65.7 per cent) but only in 5/15 (33.3 per cent) HBeAg positive patients. Only three pre-treatment variables were associated to low response HBeAg (p = 0.006), high viral load (DNA-VHB > 3 x 10(6) copies/ml) (p = 0.004) and liver HBcAg (p = 0.0028). YMDD mutations were detected in 7/11 non-responder patients.CONCLUSIONS:
HBeAg positive patients with high viral load show a high risk for developing drug resistance. On the other hand, HBeAg negative patients show a good response to lamivudine even with high viremia.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
LILACS
Assunto principal:
Lamivudina
/
Fármacos Anti-HIV
/
Hepatite B Crônica
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adolescent
/
Adult
/
Child
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Rev. Inst. Med. Trop. Säo Paulo
Assunto da revista:
MEDICINA TROPICAL
Ano de publicação:
2000
Tipo de documento:
Article
País de afiliação:
Brasil
País de publicação:
Brasil